Phaseline

Companies › Avacta Life Sciences

Avacta Life Sciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVA6000
FAP-activated doxorubicin prodrug
FAPPhase 1Salivary Gland TumorAug 2027
AVA6103
FAP-activated Exatecan
FAPPhase 1Vulvar AdenocarcinomaJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04969835AVA6000Phase 1Salivary Gland TumorOncologyAug 2027
NCT07454642AVA6103Phase 1Vulvar AdenocarcinomaOncologyJan 2029

Targets

FAP (2)

Companies with the same targets

Chengdu New Radiomedicine Technology Blue Earth Diagnostics Novartis Ratio Therapeutics Beijing Biotech SOFIE Philogen BioInvent International Lantheus Medical Imaging Perspective Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.